GlassScriptPhysician profile
Ronald William Rosenberg
NPI 1568680866
$6,063.44
in general payments reported to CMS, 2019-2025
23 companies · $1,777 in 2025
The $1,777 reported for 2025 was more than what 93% of Psychosomatic Medicine providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.27 · 2020: $125 · 2021: $602 · 2022: $802 · 2023: $924 · 2024: $1,808 · 2025: $1,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,397 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,397.37 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,232.80 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,173.63 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $699.22 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $636.67 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $343.54 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $320.21 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $273.71 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $225.93 | 2022-2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $163.15 | 2022-2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $138.68 | 2022-2025 | Qelbree |
| Axsome Therapeutics, INC. | $132.85 | 2024 | Auvelity |
| Lundbeck LLC | $121.69 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $109.01 | 2022-2025 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $107.98 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $101.86 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $84.37 | 2023-2024 | Jornay Pm |
| Almatica Pharma LLC | $63.49 | 2021-2024 | Loreev Xr |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.54 | 2023 | Aplenzin |
| Corium, LLC | $25.68 | 2023 | Azstarys |
| Tris Pharma INC | $21.84 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.35 | 2021 | |
| Novo Nordisk INC | $15.67 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $14.57 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.